Inbrija EU market potential

Discussion in 'Acorda Therapeutics' started by anonymous, May 24, 2018 at 2:19 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The various peak sales estimates seem to be based on the US market only. Are there any figures for the EU and other eventual markets?
     

  2. anonymous

    anonymous Guest

    The market for this product is the US. Other countries won’t pay a premium for convenience.
     
  3. anonymous

    anonymous Guest

    Why wouldn't the other markets pay for convenience!?

    Why would the US market pay for convenience!?
     
  4. anonymous

    anonymous Guest

    There is very little market potential in the EU. Maybe 10% of US market and as other poster said they see zero value in the 'convenience' factor. Totally different mindset in EU with their socialized med.
     
  5. anonymous

    anonymous Guest

    The price point will determine failure or possible success. You have no choice but to price high to bring the lost revenue from Ampyra. Therefore - no HCP will prescribe. It is a necessary drug. We have blundered again.
     
  6. anonymous

    anonymous Guest

    Docs often complain about high drug prices, yet few actually know the prices of the medicines they prescribed. When it comes to specific medicines, price rarely affects the prescriptions ; unless the price is quite high.

    Inbrija, even if priced at a premium, will still be prescribed, as it is effective and safe in rescuing the patient from horrible debilitating OFF
     
  7. anonymous

    anonymous Guest


    Keep believing the bullshit.
     
  8. anonymous

    anonymous Guest

    Hey Einstein, docs may not know the exact price, but payers do. Once they drop a PA or NDC block on this me-too product docs will get fed up and quit even trying. Don’t believe me? See how things are going for Acadia and Lundbeck in the PD space.

    This must be your first rodeo with your fancy MBA and Econ degree. Real life is a lot different than the classroom kid.
     
  9. anonymous

    anonymous Guest

    First of all...F YOU !!!!!
    I KNOW drug pricing theory and practice. I know we can price-point Inbrija very high as in macro economic theory it has an inelastic S-D inflection point. You moron probably dont understand this but that speaks to your lack of education. Having multi degrees including the MBA enables me to see that this is a ballbuster product and can priced as we see fit, within 'reason' of course.
     
  10. anonymous

    anonymous Guest

    I’d have mom and dad ask for their money back on those degrees kiddo. Reality is about to give you a big dose of humble pie. Assuming you gain approval to even test your theories.
     
  11. anonymous

    anonymous Guest

    Moron extraordinaire! Companies that do well are not going the route of high prices especially for Inbrija - a drug not NEEDED! Someone is inflating these boards with positive lies! Trying to sell the company for more money than was offered sir?
     
  12. anonymous

    anonymous Guest

    Fine, but if this is the case, why did Acorda bother filing an "NDA" in EU?
     
  13. anonymous

    anonymous Guest

    Is not an NDA, but Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA).
     
  14. anonymous

    anonymous Guest

    Yes, that is why I wrote "NDA", which you surely noticed ... but did not understand ... sigh

    So, you had no knowledge, whatsoever, regarding the actual question, but bothered to comment an irrelevant formality!?

    Brilliant future waiting for you in pharma :)
     
  15. anonymous

    anonymous Guest

    HEY DICKHEAD .F YOU!!!
    i know more about pharmaceuticals in my pinkie finger than you will ever, ok?
     
  16. anonymous

    anonymous Guest

    Touche' :)

    You give a whole new meaning to "hitting the soft spot" :)

    And your answer to my original question is ..... or should I wait until you finish your elementary school ... :)
     
  17. anonymous

    anonymous Guest

    Touche'

    You give a whole new meaning to "hitting the soft spot" :)

    So, what is your answer/opinion to the original question ... or should I wait until you finish your elementary school :)

    All joking aside, you may want to ask your parents what the question is all about .... no, hold on a second ... if you carry their genes it would be waste of time .... ask your teacher instead, or anyone you might meet there in the "deep river" forest :)
     
  18. anonymous

    anonymous Guest

    So, take your pinkie finger out of your arse and answer the question ... which you obviously can't :)
     
  19. anonymous

    anonymous Guest

    dont argue with Acorda’s world renown economist and pricing guru! The industry wouldn’t exist without his wisdom and insight. Just ask him.

    Oh, and don’t disagree with him. It really gets his pink panties in a bunch and mommy and daddy didn’t prepare him for that.
     
  20. anonymous

    anonymous Guest

    AGAIN F YOU multi dickhead here attacking me, ok. Will price to maximize our ROI. You don't understand customer centiment or you would see we have it, ok so you get it now you moron??